SCHEMBL6705159

SCHEMBL6705159

CC(C)=CCCC(C)CCN(C)N(C(=O)c1ccccc1)c1cnc2ccccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.40
TRPM8 Q7Z2W7 6/20 0.39
GABRA1 P14867 1/20 0.39
KDM4E B2RXH2 3/20 0.38
TSHR P16473 1/20 0.38
MAP4K4 O95819 1/20 0.38
CSNK1G2 P78368 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
MAP4K5 Q9Y4K4 1/20 0.38
MET P08581 1/20 0.38
MGAM O43451 1/20 0.36
USP2 O75604 1/20 0.36
RAB9A P51151 2/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
PDE10A Q9Y233 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846040 0.73 TRPV1 (0.67) KDM4ERAB9AALDH1A1KDRNPC1
SCHEMBL846202 0.73 TRPV1 (0.67) KDM4ERAB9AALDH1A1KDRNPC1
SCHEMBL846041 0.73 TRPV1 (0.67) KDM4ERAB9AALDH1A1KDRNPC1
SCHEMBL6705154 0.71 KDR (0.49) KDM4ETSHRRAB9AKDRNPC1
SCHEMBL28421769 0.69 NOTUM (0.52) KDM4ETSHRRAB9AMEN1KMT2A
SCHEMBL6488055 0.64 L3MBTL1 (0.45) KDM4ETSHRUSP2MEN1ALDH1A1
SCHEMBL21798451 0.63 ATM (0.45) TRPM8KDM4ETSHRUSP2ALDH1A1
SCHEMBL21798456 0.63 ATM (0.45) TRPM8KDM4ETSHRUSP2ALDH1A1
SCHEMBL21798435 0.63 ATM (0.45) TRPM8KDM4ETSHRUSP2ALDH1A1
SCHEMBL21798440 0.63 ATM (0.45) TRPM8KDM4ETSHRUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2004-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor TRPV1, OPRL1, TRPV2 CFTR 710/4885TRPM8 29/4885GABRA1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.